Omnaris and Tradjenta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 17 people who take Omnaris and Tradjenta. Common interactions include tendon rupture among females, and asthma among males.

The phase IV clinical study analyzes what interactions people who take Omnaris and Tradjenta have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 20, 2023

17 people who take Omnaris and Tradjenta together, and have interactions are studied.


What is Omnaris?

Omnaris has active ingredients of ciclesonide. It is used in allergies. Currently, eHealthMe is studying from 3,684 Omnaris users.

What is Tradjenta?

Tradjenta has active ingredients of linagliptin. It is used in diabetes. Currently, eHealthMe is studying from 9,747 Tradjenta users.

Number of Omnaris and Tradjenta reports submitted per year:

Omnaris and Tradjenta drug interactions.

Common Omnaris and Tradjenta drug interactions by gender *:

female:

  1. Tendon rupture
  2. Gastrointestinal disorder
  3. Contusion
  4. Fall
  5. Joint injury
  6. Joint swelling
  7. Post procedural infection
  8. Bronchitis
  9. Surgery
  10. Ear infection

male:

  1. Asthma
  2. Bronchial hyperreactivity
  3. Sputum discoloured
  4. Wheezing
  5. Pneumonia
  6. Sleep disorder due to a general medical condition
  7. Drug ineffective
  8. Lung disorder
  9. Lung infection
  10. Cough

Common Omnaris and Tradjenta drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Contusion
  2. Fall
  3. Gastrointestinal disorder
  4. Joint injury
  5. Joint swelling
  6. Post procedural infection
  7. Tendon rupture
  8. Surgery
  9. Limb injury
  10. Road traffic accident

60+:

  1. Asthma
  2. Bronchial hyperreactivity
  3. Sputum discoloured
  4. Wheezing
  5. Pneumonia
  6. Sleep disorder due to a general medical condition
  7. Drug ineffective
  8. Lung disorder
  9. Lung infection
  10. Cough

Common conditions people have *:

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 12 people, 70.59%
  2. Asthma: 5 people, 29.41%

* Approximation only. Some reports may have incomplete information.

Do you take Omnaris and Tradjenta?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Drug side effects by duration, gender and age:

Common Omnaris drug interactions:

Browse interactions between Omnaris and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tradjenta drug interactions:

Browse interactions between Tradjenta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ciclesonide and linagliptin (the active ingredients of Omnaris and Tradjenta, respectively), and Omnaris and Tradjenta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Omnaris and Tradjenta.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: